An interventional study of Active BFRT and Sham BFRT in Shoulder Pain, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by University of Florida · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.
Among the 146 studies in Shoulder Pain with a site in United States, this one is the 77th largest by planned enrollment of the 122 interventional ones that give a count, is one of 11 that started in 2025, is one of 78 with no phase, reaches primary completion later than 15 of the 27 other live ones, and was the 137th registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–45 · Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Prisma Health-Upstate · Sites in United States
Ages 21–65 · Women only
Lisa Griffin · Sites in United States
Ages 60+
Brigham and Women's Hospital · Sites in United States
Ages 21–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 21
First in 2003; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 60 across 590 interventional studies indexed under Shoulder Pain.
Median enrollment 50 across the 122 interventional studies, 65 across the 24 observational. Of the 101 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 146 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 2 studies filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Shoulder Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851233Rothman Institute OrthopaedicsPatient Education and Sling Use After Shoulder Surgery | 2026-11-30 |
| NCT06039345University of UtahShoulder RFA Pilot Study | 2026-12 |
| NCT07101250Prisma Health-UpstatePreoperative Acetazolamide | 2026-12-01 |
| NCT03653455Rush University Medical CenterPatient Outcomes Collection: How Can we do Better? | 2026-12-31 |
| NCT07400146Cedars-Sinai Medical CenterBupivacaine With Epinephrine Over Diaphragm in Laparoscopy | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 146 studies in Shoulder Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot clinical trial is to learn if blood flow restriction training is safe and feasible in patients with subacromial pain. The main questions the investigators aim to answer are:
The investigators will compare active blood flow restriction training to sham (an inactive procedure designed to mimic the active training as closely as possible).
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (general):
Exclusion criteria (Blood flow restriction training specific)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Active BFRT · Behavioral: Strengthening Exercises with BFRT · Behavioral: Skilled Physical Therapy Care
Device: Sham BFRT · Behavioral: Strengthening Exercises with BFRT · Behavioral: Skilled Physical Therapy Care
The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains 50% of participants limb occlusion pressure for the duration of each strengthening exercise.
The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains a pressure of 20mmHg for the duration of each strengthening exercise.
Participants perform 4 strengthening exercises while using the BFR device: seated scapular plane elevation, prone horizontal abduction, side-lying external rotation, and prone scapular plane elevation. Each exercise is performed unilaterally. Participants perform 1 set of 30 repetitions followed by 3 sets of 15 repetitions (4 total sets, 75 total repetitions). Participants are given 30 seconds rest between sets and 2 minutes of rest between strengthening exercises. Selected resistance for each strengthening exercise is equal to 20% of the participant's maximal force production as measured by handheld dynamometry. Resistance is adjusted weekly.
Participants perform non-strengthening interventions as part of skilled physical therapy care. Non-strengthening interventions include an upper arm ergometer for warm-up, active assisted range of motion of the shoulder, shoulder stretching, shoulder joint mobilizations, and cryotherapy. Non-strengthening interventions are prescribed at the discretion of the treating physical therapist. Participants are enrolled in physical therapy for a minimum of 4 weeks. After 4 weeks, the treating physical therapist can discharge a participant based on their progress in meeting their rehabilitation goals. Participants discharged from skilled physical therapy care will continue to complete strengthening exercises with BFRT until the end of the trial period (8 weeks).
Recruitment
Record the number of individuals a) approached, b) screened, c) qualified, and d) willing to participate. The reasons for participants who do not qualify or refuse to participate will be recorded.
Time frame: Monthly report from beginning to completion of recruitment (anticipated 2 years)
Intervention feasibility
The interventionist team will complete standardized notes of the intervention, which will be reviewed weekly to document adherence and protocol fidelity and for early identification of intervention deviations. Outcomes include the number of patients a) completing at least 80% of the assigned BFRT visits, b) requesting to stop BFRT within a session, c) requesting to withdraw from the intervention, and d) requesting to switch intervention arms. The last number is a proxy for patients who do not accept randomization results.
Time frame: Weekly record from enrollment to the end of treatment at 8 weeks.
Retention
Identify the number of dropouts and reasons impacting participation in follow-up visits.
Time frame: Weekly record from enrollment to 26 weeks (end of the trial).
Intervention safety
Monitor the occurrance of severe adverse events and exercise-related adverse events.
Time frame: Weekly record from enrollment to 26 weeks (end of the trial).
Participants masking feasibility
At the primary endpoint, participants will be asked to guess the treatment allocation to evaluate participant masking feasibility.
Time frame: At 8 weeks
Patient acceptability
A guided interview using Likert scale-type and open-ended questions will be conducted to gather participant feedback on trial and intervention procedures. An electronic copy of this questionnaire will be sent to patients who withdraw/stop showing up to understand whether trial or intervention procedures impact patient retention.
Time frame: At 8 weeks
Range of motion
The investigators will measure range of motion using an inclinometer or goniometer. The investigators will measure shoulder elevation in the scapular plane, external rotation, and internal rotation. The investigators will also measure coronal, axial, and sagittal rotation of the scapula during shoulder elevation in the scapular plane.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Strength
The investigators will measure shoulder elevation in the scapular plane and external rotation strength using a handheld dynamometer.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Timed Functional Arm and Shoulder Test (TFAST)
It includes three tasks: an internal/external rotation task (duration 30s), an outward circular motion task (duration 30s), and a gallon-lift task at the height of a standard counter (duration 30s). In each task, participants repeat movements as fast as possible.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Supraspinatus and infraspinatus muscle cross-sectional area
The investigators will use ultrasound to take pictures of the supraspinatus and infraspinatus muscles. This outcome represents a marker of hypertrophy, a potential mechanism of strengthening.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Supraspinatus tendon morphology
The investigators will use ultrasound to take pictures of the supraspinatus tendons. Established ultrasound procedures will be used to measure supraspinatus tendon thickness.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Supraspinatus tendon elastography
Ultrasound will be used to take pictures of the supraspinatus tendons. The investigators will set the ultrasound parameters to elastography, allowing non-invasive measurement of tendon stiffness and elasticity.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Pennsylvania Shoulder Score (PENN)
The PENN is a valid and reliable self-reported questionnaire for patients with shoulder pain.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Global rating of change (GROC)
The GROC is a rating scale that quantifies participants' improvement or deterioration of symptoms over time. Changes will be measured using a 15-points Likert scale (-7, a very great deal worse to 7, a very great deal better, with 0 indicating no changes).
Time frame: At 4 weeks, 8 weeks and 6 months
Patient specific functional scale (PSFS)
The PSFS asks patients to rate their difficulty performing three activities of their choice. It is advantageous because it asks patients to select the activities rather than providing pre-selected options.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Western Ontario Rotator Cuff Index (WORC)
The WORC is a valid and reliable tool to assess quality of life in patients with shoulder pain. The tool contains a total of 21 Likert-type questions in five different domains (Physical symptoms, Sports/Recreation/Work/Lifestyle/Emotions)
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Brief Pain Inventory (BPI)
The BPI is a reliable, primary pain recovery measure used in clinical trials of patients with shoulder pain. It measures pain across three domains (average, best, and worst).
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Patient Acceptable Symptoms State (PASS)
The PASS is a rating scale that quantifies participants' satisfaction with their current level of function in the context of clinical care.
Time frame: At 8 weeks and 6 months
Pressure pain sensitivity
The investigators will apply pressure at a constant rate using a computerized pressure algometer with a 1 cm diameter rubber tip at the shoulder and the lower limb.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Quick Disability of the Arm and Shoulder (Q-DASH)
The Q-DASH evaluates upper extremity disability while monitoring change or function over time. This assessment consists of 11 questions (3 items related to symptoms and 8 items related to functional tasks). Reliability and validity have been established for this scale.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Infraspinatus tendon morphology
The investigators will use ultrasound to take pictures of the infraspinatus tendons. Established ultrasound procedures will be used to measure infraspinatus tendon thickness.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Infraspinatus tendon elastography
Ultrasound will be used to take pictures of the infraspinatus tendons. The investigators will set the ultrasound parameters to elastography, allowing non-invasive measurement of tendon stiffness and elasticity.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Optimal Screening for Prediction of Referral and Outcome (OSPRO)
The OSPRO is a concise, multidimensional 10-item yellow flag assessment tool that estimates 11 total questionnaire scores indicating elevated vulnerability and decreased resilience.
Time frame: From enrollment to 4 weeks, 8 weeks and 6 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Study protocol \& statistical analysis plan: A manuscript describing the study protocol and statistical analysis plan will be submitted for publication within the first year of starting the clinical trial. Clinical study report and analytic code: Individual data and analytic code will be made available after the publication of the primary results of this trial.
Access criteria: Study protocol and statistical analysis plan: The manuscript will be published as open access. Clinical study report and analytic code: Data will be shared on NIH/NIAMS approvved data repository (i.e., Dataverse). Access will follow repository guidelines.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.
Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 22 months is above that.
Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.